Overall Score

Revenue Growth

Biocryst remains a commercial-stage rare-disease company with a revenue base supported by Orladeyo and other products.

The current valuation implies moderate growth expectations rather than a high-growth multiple.

Profitability

Gross margin is positive at 23.5%, but operating margin remains deeply negative at -33.3% and net margin at -40.9%.

Return on invested capital is still negative, indicating the business is not yet generating durable economic profits.

Balance Sheet

Liquidity is solid with a current ratio of 2.32 and cash ratio of 0.74.

Net debt remains manageable relative to EBITDA, supporting financial flexibility.

Cash Flow

Free cash flow generation is positive, with free cash flow yield around 14.3%.

Capital intensity is low, with capex representing a small share of revenue and operating cash flow.

Valuation

The stock trades at about 2.9x EV/sales and roughly 7.0x price/free cash flow, which is reasonable for a profitable commercial biotech.

Negative earnings and EBITDA keep traditional earnings-based valuation metrics less informative.

Growth Catalysts

Long-term upside depends on continued Orladeyo growth and pipeline execution in rare disease.

Any successful label expansion or new product contribution could improve the 10-year growth profile.

Risk Profile

Persistent operating losses and negative returns on capital remain the main structural risk.

Biotech concentration risk and execution risk on pipeline development continue to limit confidence in the long-term growth case.